Importer of Controlled Substances Application: Meridian Medical Technologies, 68473-68474 [2019-27093]
Download as PDF
<![CDATA[
68473
Federal Register / Vol. 84, No. 241 / Monday, December 16, 2019 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 731–TA–1443 (Final)]
Carbon and Alloy Steel Threaded Rod
From Taiwan; Supplemental Schedule
for the Final Phase of an Anti-Dumping
Duty Investigation
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
DATES:
December 10, 2019.
lotter on DSKBCFDHB2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Kristina Lara ((202) 205–3386), Office of
Investigations, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on
(202) 205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at (202) 205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these investigations may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION: Effective
August 7, 2019, the Commission
established a general schedule for the
conduct of the final phase of its
investigations on carbon and alloy steel
threaded rod (‘‘threaded rod’’) from
China, India, Taiwan, and Thailand,1
following a preliminary determination
by the U.S. Department of Commerce
(‘‘Commerce’’) that imports of threaded
rod from Thailand were being sold at
less than fair value (LTFV) in the United
States.2 Notice of the scheduling of the
final phase of the Commission’s
investigations and of a public hearing to
be held in connection therewith was
given by posting copies of the notice in
the Office of the Secretary, U.S.
International Trade Commission,
Washington, DC, and by publishing the
notice in the Federal Register of August
27, 2019 (84 FR 44916). The hearing was
held in Washington, DC, on October 15,
2019, and all persons who requested the
opportunity were permitted to appear in
person or by counsel. On October 21,
2019, Commerce issued a final
affirmative determination of sales at
LTFV and critical circumstances with
respect to imports of threaded rod from
Thailand.3 The Commission issued its
final affirmative determination
regarding LTFV imports of threaded rod
from Thailand on December 5, 2019.
On December 9, 2019, Commerce
issued its final affirmative
determination that imports of threaded
rod from Taiwan were being sold at
LTFV in the United States.4
Accordingly, the Commission currently
is issuing a supplemental schedule for
its antidumping investigation on
imports of threaded rod from Taiwan.
This supplemental schedule is as
follows: The deadline for filing
supplemental party comments on
Commerce’s final antidumping duty
determination is December 17, 2019.
Supplemental party comments may
address only Commerce’s final
antidumping duty determination
regarding imports of threaded rod from
Taiwan. These supplemental final
comments may not contain new factual
information and may not exceed five (5)
pages in length. The supplemental staff
report in the final phase of this
investigation regarding subject imports
from Taiwan will be placed in the
nonpublic record on January 3, 2019;
and a public version will be issued
thereafter.
For further information concerning
this investigation see the Commission’s
notice cited above and the
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A and C (19 CFR part 207).
Additional written submissions to the
Commission, including requests
pursuant to section 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with sections 201.16(c)
and 207.3 of the Commission’s rules,
each document filed by a party to the
investigation must be served on all other
parties to the investigation (as identified
by either the public or BPI service list),
and a certificate of service must be
timely filed. The Secretary will not
accept a document for filing without a
certificate of service.
Authority: This investigation is being
conducted under authority of title VII of
the Tariff Act of 1930; this notice is
published pursuant to section 207.21 of
the Commission’s rules.
By order of the Commission.
1 84
FR 44916, August 27, 2019.
FR 38597, August 7, 2019.
3 84 FR 56162, October 21, 2019.
2 84
VerDate Sep<11>2014
19:21 Dec 13, 2019
4 84
Jkt 250001
PO 00000
FR 67258, December 9, 2019.
Frm 00082
Fmt 4703
Sfmt 4703
Issued: December 10, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–26975 Filed 12–13–19; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–564]
Importer of Controlled Substances
Application: Meridian Medical
Technologies
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 15, 2020. Such
persons may also file a written request
for a hearing on the application on or
before January 15, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on November 13, 2019,
Meridian Medical Technologies, 2555
Hermelin Drive, Saint Louis, Missouri
63144 applied to be registered as an
importer of the following basic class of
controlled substance:
DATES:
Controlled substance
Drug
code
Schedule
Morphine .........................
9300
II
The company manufactures a product
containing morphine in the United
States. The company exports this
product to customers around the world.
The company has been asked to ensure
that its product, which is sold to
European customers, meets the
standards established by the European
Pharmacopeia, administered by the
E:\FR\FM\16DEN1.SGM
16DEN1
68474
Federal Register / Vol. 84, No. 241 / Monday, December 16, 2019 / Notices
Directorate for the quality of Medicines
(EDQM). In order to ensure that its
product will meet European
specifications, the company seeks to
import morphine supplied by EDQM for
use as reference standards.
DEPARTMENT OF JUSTICE
[Docket No. DEA–553]
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
Authorization will not extend to the
import of Food and Drug
Administration approved or nonapproved finished dosage forms for
commercial sale.
Drug Enforcement Administration
Importer of Controlled Substances
Application: Mylan Pharmaceuticals
Inc.
Dated: November 14, 2019.
William T. McDermott,
Assistant Administrator.
Dated: December 2, 2019.
William T. McDermott,
Assistant Administrator.
Drug Enforcement Administration
[Docket No. DEA–560]
[FR Doc. 2019–27094 Filed 12–13–19; 8:45 am]
Importer of Controlled Substances
Application: Novitium Pharma LLC
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 15, 2020. Such
persons may also file a written request
for a hearing on the application on or
before January 15, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR
1301.34(a), this is notice that on July 18,
2018, Novitium Pharma, LLC., 70 Lake
Drive, East Windsor, New Jersey 08520
applied to be registered as an importer
of the following basic class of controlled
substance:
DATES:
Levorphanol ..............
Drug
code
9220
19:21 Dec 13, 2019
BILLING CODE 4410–09–P
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 15, 2020. Such
persons may also file a written request
for a hearing on the application on or
before January 15, 2020
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR
1301.34(a), this is notice that on October
17, 2019, Mylan Pharmaceuticals Inc.,
3711 Collins Ferry Road, Morgantown,
West Virginia 26505 applied to be
registered as an importer of the
following basic classes of controlled
substances:
Controlled substance
Drug
code
Schedule
Amphetamine .................
Methylphenidate .............
Oxycodone .....................
Hydromorphone ..............
Methadone ......................
Morphine .........................
Fentanyl ..........................
1100
1724
9143
9150
9250
9300
9801
II
II
II
II
II
II
II
Schedule
II
The company plans to import the
controlled substance to develop the
manufacturing process for a drug
product that will in turn be used to
VerDate Sep<11>2014
Notice of application.
DATES:
Notice of application.
Controlled substance
[FR Doc. 2019–27095 Filed 12–13–19; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
ACTION:
Dated: December 3, 2019.
William T. McDermott,
Assistant Administrator.
BILLING CODE 4410–09–P
[FR Doc. 2019–27093 Filed 12–13–19; 8:45 am]
lotter on DSKBCFDHB2PROD with NOTICES
produce a tablet equivalent to the
current brand product.
Jkt 250001
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Jeffrey D. Olsen, M.D.; Decision and
Order
On August 2, 2016, a former Acting
Administrator of the Drug Enforcement
Administration (hereinafter, DEA or
Government), issued an Order to Show
Cause (OSC) and Immediate Suspension
of Registration (ISO) to Jeffrey D. Olsen,
M.D. (hereinafter, Registrant), of
Newport Beach, CA. Order to Show
Cause and Immediate Suspension of
Registration (hereinafter collectively,
OSC 2)), at 1; see also Government
Exhibit (hereinafter, GX) 26, at 1–6. OSC
2 informed Registrant of the immediate
suspension of his DEA Certificate of
Registration (hereinafter, COR)
FO6043638 pursuant to 21 U.S.C. 824(d)
‘‘because . . . [his] continued
registration constitute[d] an imminent
danger to the public health and safety.’’
Id.
The substantive ground for the
proceeding, as alleged in OSC 2, was
that Registrant’s ‘‘continued registration
is inconsistent with the public interest,
as that term is defined in 21 U.S.C.
823(f).’’ Id. (citing 21 U.S.C. 824(a)(4)).
Specifically, the OSC alleged that
Registrant issued numerous
prescriptions outside the usual course of
the professional practice of medicine in
violation of 21 U.S.C. 841(a)(1) and 21
CFR 1306.04(a) and in violation of
California law and the minimum
standards of medical practice in
California. Id. at 2–4. The OSC stated
that ‘‘[Registrant’s] conduct, viewed as a
whole, ‘completely betrayed any
semblance of legitimate medical
treatment.’’’ Id. at 4 (citing Jack A.
Danton, D.O., 76 FR 60900, 60904
E:\FR\FM\16DEN1.SGM
16DEN1
]]>Agencies
[Federal Register Volume 84, Number 241 (Monday, December 16, 2019)]
[Notices]
[Pages 68473-68474]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27093]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-564]
Importer of Controlled Substances Application: Meridian Medical
Technologies
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before January 15, 2020.
Such persons may also file a written request for a hearing on the
application on or before January 15, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on November 13, 2019, Meridian Medical Technologies,
2555 Hermelin Drive, Saint Louis, Missouri 63144 applied to be
registered as an importer of the following basic class of controlled
substance:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Morphine............................... 9300 II
------------------------------------------------------------------------
The company manufactures a product containing morphine in the
United States. The company exports this product to customers around the
world. The company has been asked to ensure that its product, which is
sold to European customers, meets the standards established by the
European Pharmacopeia, administered by the
[[Page 68474]]
Directorate for the quality of Medicines (EDQM). In order to ensure
that its product will meet European specifications, the company seeks
to import morphine supplied by EDQM for use as reference standards.
Dated: December 2, 2019.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2019-27093 Filed 12-13-19; 8:45 am]
BILLING CODE 4410-09-P
